THERAVLINFO
network transpyrenees of advanced therapies in non-Hodgkin's lymphoma
The University of Navarra participates in an international project that seeks to develop new immunotherapy strategies for the treatment of non-Hodgkin's lymphoma.
The project of research THERAVLINFO paims to promote innovation in health and biomedical research in the Catalonia-Occitania-Navarre area through the partnership between universities, centers research, hospitals, biotechnology companies and other agents in the POCTEFA region.
What are we looking for?
THERAVLINFO (EFA123/1) is an effort to advance the biomedical translation of the knowledge and preclinical lymphoma models generated at the previous project IMLINFO (EFA 281/16), with the goal goal of improving the survival and quality of life of patients with non-Hodgkin's lymphoma (NHL). The project IMLINFO succeeded in establishing a archive of lymphoma patient samples, developing a 3D culture platform that recapitulates the disease in vitro, and designing a flow of work to screen for antitumor drugs. As result, new targets involved in evasion of the anti-tumor immune response and immunosuppression were identified, which show promising therapeutic potential that will be further investigated thanks to the THERAVLINFO cross-border cooperation.
What do we do?
THERAVLINFO will develop drugs against these new targets (antibodies, CAR-T cell therapy and nanocapsules) and will validate their therapeutic potential in preclinical in vitro multicellular 3D culture models and in vivo in murine models. The project seeks as its maingoal to drive innovation in the Southern European healthcare sector with the development of new advanced therapies in personalized medicine for NHL lymphoma patients who do not respond to standard treatment, relapse early or transform to aggressive lymphoma. The project includes the cooperation of experts in patient-derived lymphoma spheroid culture, animal models, multiparametric cytometry, confocal microscopy, omics technologies and computational analysis. In addition, the project seeks to foster the training of young researchers who can integrate and rotate among the cross-border partners, and to foster collaborations with biotechnology companies in the region (NUCAPS and ONA Therapeutics).
FUNDING
The project has ERDF funding of €993,303.67.
budget total: 1.528.159,52€.
CALENDAR
The project will be developed over three years (2024-2026).
COOPERATION
Collaborations will be generated between the partners of project to enhance the research
Objectives
Strengthen cooperation between the different actors of the territory on both sides of the border at subject of research and development+i.
Establish a stablenetwork of partnership between universities, research, hospitals and companies.
To develop new immunotherapy strategies against 4 non-Hodgkin's lymphoma tumor targets, opening new opportunities in the health field.
Design new routes of administration of immunotherapy treatments to improve their accessibility and clinical applicability.
Our participation
The University of Navarra plays a key role in the consortium, focusing on developing murine models of lymphoma and generating preclinical evidence to demonstrate the in vivo therapeutic efficacy of the new immunotherapy strategies designed within THERAVLINFO. In addition, it contributes to investigating their mechanisms of action and the possibility of administering these therapies orally using the natural nanotechnology developed by the business NUCAPS.
Together with the University of Navarra, four other public institutions from Catalonia and Occitania make up the project . Under the coordination of the Fundació de Recerca Clínic Barcelona-IDIBAPSthis project responds to the strategic interest of all the centers involved in boosting their innovation and competitiveness through the integration of their multiple competences in biomedical research , biotechnology and clinical translation.
Financing
The project THERAVLINFO (EFA123/1) is co-financed by the Interreg POCTEFA 2021-2027 program for 3 years.
Partners
